SFW Capital, a private equity firm focused on partnering with founder-led firms in the industrial and life sciences technology sector, has completed a strategic investment in Sannova Analytical, a contract research organization.

Sannova focuses on bioanalytical and chemistry manufacturing and controls testing services for pharmaceutical and biotech customers. The firm’s services are utilized across drug development, manufacturing and assessment of safety and efficacy.

“We are very excited to partner with the team at Sannova to build on their tremendous success and enhance the value they provide to major pharmaceutical and biotech companies in the U.S. and around the world,” said Roger Freeman, co-founder and partner at SFW. “The Company is well positioned to take advantage of major industry trends, particularly the increasing tendency of biopharmaceutical companies to outsource critical activities to specialized CROs that can deliver high-quality services with great efficiency. We believe Sannova’s growth can be further accelerated through diversifying the breadth of its service offering, generating greater awareness of its capabilities in the market, and pursuing strategic acquisitions.”